

COURT FILE NUMBER **2503 23802**

COURT COURT OF KING'S BENCH OF ALBERTA

JUDICIAL CENTRE EDMONTON

APPLICANTS IN THE MATTER OF THE COMPANIES' CREDITORS
ARRANGEMENT ACT, R.S.C. 1985, C. C-36, AS AMENDED

AND IN THE MATTER OF A PLAN OF COMPROMISE OR
ARRANGEMENT OF SUNERA ACREAGE HOLDINGS INC.,
ACREAGE DEVELOPMENT CORP., SIRONA FARMS INC., and
2834015 ALBERTA LTD.

DOCUMENT **SIXTH REPORT OF ERNST & YOUNG INC. IN ITS CAPACITY AS
THE MONITOR OF THE APPLICANTS**

September 21, 2026

ADDRESS FOR
SERVICE AND
CONTACT
INFORMATION OF
PARTY FILING THIS
DOCUMENT

MONITOR

Ernst & Young Inc.
EPCOR Tower
10423 – 101 Street, Suite 1400
Edmonton, Alberta T5H 0E7
Attention: Matt McCulloch / Karen Zahacy
Telephone: 780.638.6642 / 780.412.2384
Fax: 780.428.8977
Email: matt.mcculloch@parthenon.ey.com
karen.zahacy@parthenon.ey.com

MONITOR'S COUNSEL

McLennan Ross LLP
600, McLennan Ross Building
12220 Stony Plain Rd.
Edmonton, Alberta T5N 3Y4
Attn: Ryan Trainer / Kevin Hoy
Telephone: 780.482.9153 / 403.303.2934
Email: ryan.trainer@mross.com
kevin.hoy@mross.com

TABLE OF CONTENTS OF THE SIXTH REPORT OF THE MONITOR

Introduction.....	3
Purpose	5
Terms of Reference and Disclaimer	7
Background	7
Activities of the Monitor Since The Filing of the Supplement to the Monitor’s Fifth Report.....	7
Further Gupta Communications	8
Creditor Matters	9
Boersma Application	9
Fees and Expenses of the monitor and its Counsel	16
Cash Flow and Proposed Distribution to Charge Beneficiaries	17
Remaining Funds	20
Proposed Discharge of the CRO	21
Remaining Activities of the Monitor.....	22
Proposed Termination of the CCAA and Discharge of the Monitor	22
Revised Stay Extension	22
Recommendations	23

SCHEDULES

Schedule A	Amendment to the Sinclair Range Engagement Agreement
Schedule B	Fee Reconciliation
Schedule C	Fee Affidavit
Schedule D	Cash Flow and Proposed Distribution

INTRODUCTION

1. On November 21, 2025, SuneRa Acreage Holdings Inc. ("**SuneRa**"), Sirona Farms Inc. ("**Farms**"), Sirona Pharma Inc. ("**Sirona Pharma**"), and Acreage Development Corp ("**Acreage Development**"), collectively referred to herein as the "**Applicants**", or the "**Companies**" were granted protection and permission to commence proceedings under the *Companies' Creditors Arrangement Act*, R.S.C. 1985, C-36 (the "**CCAA**") pursuant to an Order of this Honourable Court (the "**Initial Order**").
2. The Initial Order appointed Ernst & Young Inc. as Monitor ("**EY**" or the "**Monitor**") in the CCAA proceedings and established the Stay Period in favour of the Applicants until November 28, 2025.
3. Capitalized terms not defined herein are as defined in the Initial Order, the Pre-Filing Report, the Monitor's First to Fourth Reports or other materials filed by the Applicants in connection with this CCAA proceeding.
4. On November 25, 2025, the Applicants filed a Notice of Application that was heard by this Honourable Court on November 28, 2025, (the "**Comeback Application**").
5. At the Comeback Application the Applicants were granted the following relief:
 - a) an Amended and Restated Initial Order ("**ARIO**"), which included:
 - i. an extension of the Stay Period up to and including February 13, 2026, or such further and other date as this Court may consider appropriate;
 - ii. a key employee retention plan (the "**KERP**") and corresponding charge to secured obligations under the KERP up to \$30,000 ("**KERP Charge**");
 - iii. an increase to the Administration Charge from \$250,000 to \$500,000; and
 - iv. an increase to the Interim Financing Charge from \$280,000 to \$825,000.
 - b) an Order sealing the Confidential Supplement to the Chiasson Affidavit No.2, sworn November 25, 2025, and the Confidential Supplement to the Monitor's First Report (the "**Sealing Order**").
6. Further to the relief noted above, the Applicants sought an Order declaring that the Applicants and their former employees (the "**Former Employees**") meet the criteria established by section 3.2 of the *Wage Earner Protection Program Act* Regulations, SOR 12008-222, but the Applicants' request for relief in this regard was adjourned at the request of the Crown.

7. On February 6, 2026, the Companies obtained the following relief:
 - a) A Stay Extension, Approval of Amended Interim and Financing and Updating Chief Restructuring Officer Order (the “**February 6 Order**”) which included:
 - i. an extension of the Stay Period up to and including May 13, 2026, or such further and other date as this Court may consider appropriate;
 - ii. the Amended and Restated Interim Financing Agreement;
 - iii. an increase to the Interim Financing Charge from \$825,000 to \$2,325,000;
 - iv. the replacement Mr. Gord Boersma (“**Boersma**”) with Mr. David Blair (“**Blair**”) as the Chief Restructuring Officer (the “**CRO**”); and
 - b) an Order sealing the sealing the Confidential Supplement to Chiasson Affidavit No.3.
8. On May 8, 2026, the Companies obtained an Order approving an extension of the Stay Period up to and including May 21, 2026.
9. Upon the Companies’ Application returnable on May 20, 2026 (the “**SISP Application**”), the Companies obtained an Order (the “**SISP Order**”) of this Honourable Court approving:
 - a) an extension of the Stay Period up to and including July 17, 2026, or such further and other date as this Court may consider appropriate;
 - b) expansion of the Monitor’s powers (the “**Monitor’s Expanded Powers**”);
 - c) the Second Interim Financing Agreement and a Second Interim Financing Charge in the amount of \$100,000; and
 - d) approval of a sales and investment solicitation process (the “**SISP**”).
10. On July 13, 2026, the Monitor obtained an Order approving an extension of the Stay Period up to and including August 31, 2026 (the “**August 31 Stay Extension Order**”), with the following relief requested by the Monitor adjourned to July 31, 2026:
 - a) releases of current directors and officers as per the terms of the KERP; and
 - b) the Second Administration Charge in the amount of \$250,000.

11. On July 13, 2026, the Monitor also obtained an Approval and Reverse Vesting Order (the “**RVO**”) approving:
- a) the July 3, 2026, Subscription Agreement as between the Monitor and Conex Services Inc. (“**Conex**”) and the transaction (the “**Conex Transaction**”) contemplated therein;
 - b) the replacement of Sirona Pharma in these proceedings with 2834015 Alberta Ltd. (the “**Residual Co.**”);
 - c) the vesting in Residual Co. all liabilities, contracts, and encumbrances of or relating to Sirona Pharma not expressly assumed or retained pursuant to Subscription Agreement; and
 - d) release of the Monitor, its legal counsel, the Applicants, the Applicants’ legal counsel, the current and former directors and officers of the Applicants and Residual Co., amongst certain other persons, from any and all claims or liabilities pertaining to these CCAA proceedings or the Transaction.
12. On July 31, 2026, the Monitor obtained an Order of the Honourable Justice Little (the “**July 31 Order**”) approving:
- a) an increase to the Administration Charge from \$500,000 to \$1,050,000;
 - b) an extension of the Stay Period to October 31, 2026;
 - c) the proposed distribution to the Interim Lender of the Sapphire Distribution Amount;
 - d) the D&O Released Claims; and
 - e) a No Contact Order (as defined later in this Monitor’s Sixth Report)

PURPOSE

13. The purpose of this Sixth Report of the Monitor (the “**Monitor’s Sixth Report**”) is to provide this Honourable Court and the Applicants’ stakeholders with information and the Monitor’s comments with respect to the following:
- a) an update on the activities of the Monitor since the Supplement to the Monitor’s Fifth Report to the Court dated July 25, 2026;
 - b) an update on Gupta communications;
 - c) an update on creditor matters discovered addressed by the Monitor;

- d) an update on the SISP Expenses incurred by the Monitor;
- e) the Boersma Application;
- f) the professional fees and disbursements of the Monitor and those of its counsel over the course of these CCAA Proceedings;
- g) a cash flow statement prepared by the Monitor detailing the actual cash flows for the period of to September 10, 2026, and an estimate of costs to close;
- h) the proposed distribution to parties in relation to amounts owed under the various Charges in these CCAA Proceedings and the Monitor's proposed course of action on any remaining funds, if applicable;
- i) the Monitor's proposal that the CRO be discharged;
- j) the details of the Remaining Activities (defined later in this report) of the Monitor to complete these CCAA proceedings;
- k) proposed termination of these CCAA Proceedings and discharge of the Monitor; and
- l) an extension of the Stay Period to December 31, 2026 (the "**Revised Stay Extension**" or the "**Revised Stay Extension Date**").

and to serve as support for the Monitor's request for Orders that approves the:

- m) activities of the Monitor as outlined herein;
- n) fees and expenses of the Monitor through to September 3, 2026, and its counsel through to September 10, 2026;
- o) proposed distribution to creditors, detailed later in this Monitor's Sixth Report;
- p) remittance of the Remaining Funds (as defined in later in this Monitor's Sixth Report) to this Honourable Court to be held in trust;
- q) discharge of the CRO David Blair;
- r) discharge of the Monitor of the Applicants and termination of these CCAA proceedings upon the Monitor filing the Monitor's Termination Certificate with the Clerk of the Court evidencing that all steps required to complete these CCAA proceedings have been completed as required;

- s) Revised Stay Period to December 31, 2026; and
- t) such further relief, advice and direction that the Court considers just and warranted in the circumstances.

TERMS OF REFERENCE AND DISCLAIMER

- 14. In preparing this Monitor's Sixth Report, the Monitor has been provided with, and has relied upon certain information, including unaudited financial information of the Companies, various copies of or excerpts of the Companies' books and records, and discussions with the Applicants' Management (collectively, the "**Information**").
- 15. Except as described in this report, the Monitor has not audited, reviewed or otherwise attempted to verify the accuracy or completeness of the Information in a manner that would comply with Canadian auditing standards pursuant to the Chartered Professional Accountants of Canada Handbook.
- 16. Future oriented information referred to in this Monitor's Sixth Report was prepared based on the Monitor's estimates and assumptions. Readers are cautioned that since forecast are based upon assumptions about future events and conditions that are not ascertainable; the actual results may vary from the forecast, and the variances may be material.
- 17. All references to dollars are in Canadian dollars.

BACKGROUND

- 18. The Applicants historically operated in the cannabis field, cultivating, processing, and distributing wholesale medical cannabis. At no point during the course of the CCAA proceedings did the Companies cultivate, process or distribute wholesale medical cannabis and the primary assets of the Companies were sold pursuant to the RVO.
- 19. Further, additional background information on the Applicants and the CCAA proceedings is available on the Monitor's website, located at www.ey.com/ca/sirona (the "**Monitor's Website**").

ACTIVITIES OF THE MONITOR SINCE THE FILING OF THE SUPPLEMENT TO THE MONITOR'S FIFTH REPORT

- 20. Since the Supplement to the Monitor's Fifth Report the activities of the have Monitor included, but were not limited to:
 - a) preparing the Second Supplement to the Monitor's Fifth Report and the related schedules;

- b) attending court on July 31, 2026;
- c) monitoring, assisting and facilitating the Applicants' cash flows;
- d) participating in numerous discussions and meetings with Management, various counsel, consultants, creditors and other stakeholders with respect to the current status of the CCAA proceedings;
- e) facilitating the closing of the Transaction on July 24, 2026, and the various post closing requirements therein; and
- f) preparing this Monitor's Sixth Report and the related schedules.

FURTHER GUPTA COMMUNICATIONS

21. On July 31, 2026, the Monitor sought and obtained an Order (No Contact), granted by the Honourable Justice Little (the "**No Contact Order**"), concerning Dr. Jagdeep Gupta, a former director of Sirona Pharma. The Monitor sought the No Contact Order to address threats of violence communicated by Dr. Gupta to numerous parties to the Service List and other persons with no interest in these proceedings. The No Contact Order prohibits Dr. Gupta from contacting the Service List (subject to limited exceptions) or certain identifiable persons directly, including the representatives of the Monitor. Legal counsel to the Monitor immediately notified Dr. Gupta via of the No Contact Order upon its granting. On August 7, 2026, Dr. Gupta acknowledged his receipt of the July 31, 2026, email of the Monitor's counsel concerning the No Contact Order.
22. On September 8, 2026, Dr. Gupta contacted the Monitor, amongst other persons, via email in contravention of the No Contact Order. Legal counsel to the Monitor immediately contacted Dr. Gupta on September 8, 2026, to reiterate that he is prohibited from communicating with the Monitor directly. On September 10, 2026, Dr. Gupta sent further email setting out express threats of violence. On September 10, 2026, legal counsel to the Monitor contacted Dr. Gupta via email to demand that he comply with the No Contact Order and that he cease and desist from sending further communications in contravention of the No Contact Order. The Monitor has notified the Royal Canadian Mounted Police of Dr. Gupta's communications. The Monitor has determined that it is unable at this time to bring forward an Application to hold Dr. Gupta in Contempt of Court, as the Monitor has no knowledge of Dr. Gupta's whereabouts and thus cannot comply with the requirement to effect personal service of a Contempt Application upon Dr. Gupta, as prescribed by Rule 10.52(1) of the *Rules of Court*.

CREDITOR MATTERS

Canada Revenue Agency (“CRA”) GST Refund and Trust Exam

23. The Monitor has engaged in numerous discussions with the CRA pertaining to the status of the Companies’ accounts and filings. As a result, the Monitor has been advised that Sirona Pharma has a GST credit in the amount of approximately \$40,000. To be eligible to receive the GST refund, various filings are required to be completed by the Monitor including but not limited to T2 returns for the periods starting August 1, 2023, to December 31, 2025, as well as various GST returns.
24. The Monitor has initiated steps to complete the required returns or otherwise obtain the appropriate exemptions to file from the CRA (as applicable). As of the date of this Monitor’s Sixth Report, the Monitor has not obtained the GST refund and is currently in the process of doing so with no estimate on when this process will be completed.
25. On or around September 16, 2026, the CRA initiated a trust exam of the Sirona Pharma pre-CCAA and post-CCAA accounts. The Monitor has provided the CRA with the information required for the CRA to complete the post-CCAA trust exam. Further, the Monitor has discussed with the CRA the lack of books and records for the pre-CCAA periods and provided the CRA with the limited information available to the Monitor for pre-CCAA periods.
26. As of the date of this Monitor’s Sixth Report, the timing and outcome of the trust examination remain uncertain. The Monitor has reserved an estimated \$3,500.00 representing the average source deductions for one period during the CCAA proceedings, to address any fees or penalties that may be assessed in connection with the post-filing trust exam.

WEPPA

27. As detailed later in this Monitor’s Sixth Report, there are limited funds available to administer the remainder of the CCAA, including the potential administration of WEPPA. As of the date of this Monitor’s Sixth Report no WEPPA order has been granted in these CCAA Proceedings and the Monitor believes there are insufficient funds to do so. Further, the Monitor expects that should a WEPPA Order be sought, it is the CRA’s intention to oppose any such order.

BOERSMA APPLICATION

28. Boersma has filed an application (the “**Boersma Application**”) seeking various relief, including, without limitation, monetary claims estate of the CCAA Applicants. The Monitor’s response to the Boersma Application are addressed below.

29. Effective February 6, 2026, Blair replaced Boersma as CRO.

Indemnification of Legal Costs

30. Boersma is seeking an indemnification for his legal counsel's involvement in matters pertaining to these CCAA proceedings. The Monitor opposes Boersma's claim for indemnification of legal costs out of the Companies' estate.
31. Sirona Pharma engaged Sinclair Range Inc. ("**Sinclair Range**") in connection with these proceedings pursuant to an engagement letter, dated October 14, 2025, (the "**Sinclair Range Engagement Agreement**"). The Sinclair Range Engagement Agreement includes the following indemnity:

[Sirona Pharma] agrees to indemnify and hold harmless Sinclair Range, each of its subsidiaries and each of their respective directors, officers, employees, partners, agents, Grand Arc Bend Inc. (Gord Boersma), including each other person, if any, controlling Sinclair Range or any of its subsidiaries and each shareholder of Sinclair Range (individually, an "Indemnified Party"), from and against any and all **losses, expenses, claims (including shareholder actions, derivative or otherwise), actions, damages and liabilities**, joint or several, including the aggregate amount paid in reasonable settlement of any actions, suits, proceedings, investigations or claims and the reasonable fees and expenses of their counsel **that may be incurred in advising with respect to and/or defending any action, suit, proceeding, investigation or claim that may be made or threatened against any Indemnified Party** or in enforcing this indemnity (collectively the "Claims") to which any Indemnified Party may become subject or otherwise involved in any capacity **insofar as the Claims relate to, are caused by, result from, arise out of or are based upon, directly or indirectly, Sinclair Range's advisory services provided pursuant to this agreement.**

[Emphasis added]

32. As the Monitor understands, the claims of Boersma, and the costs incurred thereof, primarily relate to the payment of fees and are not Claims (as defined in the Sinclair Range Engagement Agreement) that result from advisory services provided by Sinclair Range and the Monitor has not identified any Claim made against Mr. Boersma requiring the engagement of his legal counsel. As such, the Monitor believes the Sinclair Range Engagement Letter indemnity in this context is not applicable and that Boersma's legal costs, which appear to have been incurred predominately or entirely in connection with steps taken by Boersma to advance his own claims for remuneration,

should not be born by the stakeholders of these CCAA Proceedings.

33. On or about February 4, 2026, the Companies and Sinclair Range executed an amendment to the Sinclair Range Engagement Agreement, a copy of which is appended to this report as **Schedule “A”**.

Fees and Expenses claimed by Boersma

34. Pursuant to Boersma Affidavit No.3 the following amounts are claimed by Boersma:
- a) \$24,542.72 for Grand Arc Bend Inc.'s (“**Grand Arc**”) portion of fees earned up to February 6, 2026, paid to Sinclair Range but not remitted to Grand Arc;
 - b) \$1,899.53 in expenses incurred January 20-22, 2026 (the “**Boersma Expense Reimbursement**”);
 - c) \$56,250.00 for Grand Arc's 75% share of the \$75,000.00 interim financing bonus fee;
 - d) an estimated amount calculated by Boersma of \$118,125.00 representing 75% of the approximate fees earned by Sinclair Range as part of CFS#3;
 - e) a \$50,000 estimate for legal fees accrued in relation to this matter (as discussed above);
 - f) a claim for a portion of a 5% transaction bonus fee payable on the Sale of the Sirona Pharma; and
 - g) any sales taxes owed on the amounts above.
35. The Monitor has determined that the Boersma Expense Reimbursement amount appears to have been incurred in connection with Boersma’s duties as CRO. Neither the CCAA Applicants nor the Monitor appear to have made payment to Sinclair Range previously for the Boersma Expense Reimbursement amount. Accordingly, the Monitor has determined that the Boersma Expense Reimbursement amount appears to be an amount owing to Boersma secured by the Administration Charge.
36. Aside from the Boersma Expense Reimbursement amount, the Monitor does not believe that any other amounts are payable to Boersma out of the residual assets of the CCAA Applicants to the detriment of their stakeholders.

Fee Reconciliation

37. The Monitor has prepared a reconciliation of amounts paid by the Companies pursuant to the

Sinclair Range Engagement Agreement (the “**Fee Reconciliation**”) since the onset of these CCAA Proceedings which has been attached as **Schedule “B”**. As is explained in greater detail below, the CCAA Applicants and/or the Monitor appear to have made payments to Sinclair Range for the fees to which Boersma claims an interest.

38. The Fee Reconciliation shows three invoices numbered 1591, 1592 and 1593 as outstanding for the financing, CRO and bookkeeping mandate for the period of May 16, 2026, to June 22, 2026, totalling \$36,985.30. During the week ending September 11, 2026, the Monitor resolved with Sinclair Range that fair compensation for the three outstanding invoices is \$21,235.30. The Monitor has yet remit any payment to Sinclair Range for these invoices and has proposed to do so as part of the distribution relief sought and discussed elsewhere in this Monitor’s Sixth Report.
39. The Companies have paid in full all invoices issued under the Sinclair Range Engagement Agreement for services rendered from November 16, 2025, to May 21, 2026. Boersma claims \$24,542.72 for amounts paid to Sinclair Range but not remitted to Grand Arc in respect of the period during which he served as CRO, through February 6, 2026. Any further payment by the Companies, including under the Administration Charge, would duplicate amounts already paid by the estate and prejudice other creditors. Accordingly, the Monitor believes that Boersma’s claim lies against Sinclair Range, not the Companies, which have satisfied their payment obligations.
40. Boersma also claims an estimated \$118,125.00, representing 75% of the amounts paid to Sinclair Range in connection with CFS#3. Boersma Affidavit No. 3 includes a copy of the engagement agreement between Sinclair Range and Grand Arc, which provides that “Sinclair Range shall pay to Grand Arc 75% of all compensation received by Sinclair Range related to a Customer Agreement.” As shown in the Fee Reconciliation, the Companies have paid in full all invoices for the period from November 16, 2025, to May 21, 2026. Payment of the three remaining invoices is addressed in the proposed distribution discussed elsewhere in this report. Any further payment by the Companies, including under the Administration Charge, for fees already paid to Sinclair Range would duplicate amounts paid by the estate and prejudice other creditors. Accordingly, the Monitor believes that Boersma’s claim lies against Sinclair Range, not the Companies, which have satisfied their payment obligations.
41. Boersma also claims a portion of the \$75,000.00 financing success fee (the “**Financing Success Fee**”) earned in connection with the increase to the Interim Financing Facility. According to the Affidavit of Scott Sinclair sworn July 24, 2026 (“**Sinclair Affidavit No. 1**”), the success fee was assigned to the Interim Lender by Sinclair Range. Pursuant to the July 31 Order, the Monitor paid the sum of \$78,750.00, being the Financing Success Fee, plus GST, in trust to legal counsel for Sinclair Range. Consequently, the Monitor is of the view that Boersma’s potential claims concerning

the Financing Success Fee may only be made against the amounts held in trust by counsel for Sinclair Range and may not be made against the estate of the CCAA Applicants.

42. Pursuant to the February 6 Order, paragraph 34 of the ARIO was amended to appoint Blair as CRO, effective that date.
43. Grand Arc was paid an amount totalling \$58,964.71 in accordance with paragraph 17 of the February 6 Order which states that "Sinclair Range and Mr. Boersma agree that the amount of \$77,667.84 currently owed by the Applicants to Sinclair Range under the terms of the CRO Agreement shall be paid as follows: (i) \$58,964.71 to Gord Boersma and/or Grand Arc Bend; and (ii) \$18,703.13 to Sinclair Range".
44. The total fees invoiced and paid pursuant to the Sinclair Range Engagement Agreement are detailed in the Fee Reconciliation and summarized below:
 - a) the total of the fees invoiced amount to \$373,536.48;
 - b) \$226,198.94 was paid to Sinclair Range;
 - c) \$51,450.00 was paid directly to Northern Lights for CRO services rendered pursuant to the Sinclair Range Engagement Agreement for the period starting with the February 6 Order to commencement of the Northern Lights CRO Engagement Agreement;
 - d) \$58,964.71 was paid to Grand Arc; and
 - e) an unpaid balance of \$36,922.83 which relate primarily to three invoices for the period around when the Monitor was granted Expanded Powers and for which the Monitor proposes a further distribution to Sinclair Range in the amount of \$21,235.30 which has been agreed upon with Sinclair Range to be a reasonable payment for services rendered during that period (as discussed later in this Monitor's Sixth Report). Should this distribution to Sinclair Range be approved by this Honourable Court, the total fees paid to Sinclair Range would be \$247,434.24.

Transaction Bonus Fee

45. The Sinclair Range Engagement Agreement expressly contemplated Sinclair Range serving in an advisory role to the CCAA Applicants with respect to potential transactions for the sale of Sirona Pharma. The Sinclair Range Engagement Agreement provided that Sinclair Range would receive a Bonus Fee (as defined in the Sinclair Range Engagement Agreement) upon the completion of a

transaction for the sale of Sirona Pharma in the amount of 5% of the cumulative value of the transaction (the “**Transaction Bonus Fee**”).

46. On May 19, 2026, Sinclair Range contacted the CCAA Applicants to terminate the Financing component of its engagement (as defined in the Sinclair Range Engagement Agreement). Sinclair Range’s termination of the Financing component occurred one day prior to the Companies obtaining the SISP Order, which enhanced the Monitor’s powers, placing the Monitor in effective control of the CCAA Applicants, and authorizing the Monitor to conduct the SISP.
47. The Monitor conducted the SISP without relying, or materially relying, upon the transaction advisory services of Sinclair Range. During the pendency of the SISP, the Monitor together with its legal counsel, were exclusively responsible for, without limitation, the following matters pertaining to the SISP:
 - a) marketing the opportunity presented by the SISP;
 - b) preparing diligence materials, outreach to and engagement with potential SISP participants;
 - c) negotiating the terms of the Subscription Agreement;
 - d) obtaining the RVO;
 - e) completing the pre-closing reorganization of Sirona Pharma; and
 - f) closing the Conex Transaction.
48. Sinclair Range and Boersma had no material involvement in the Conex Transaction.
49. Sinclair Range has agreed that it will not seek payment of a Transaction Bonus Fee.
50. As detailed in the Monitor’s Fifth Report, on July 15, 2026, the Monitor notified Sinclair Range in writing that it considered Sinclair Range to have repudiated the Sinclair Range Engagement Agreement with Sirona Pharma. At that time, the Monitor informed Sinclair Range that it took the position that Sinclair Range would not be entitled to receive the Transaction Bonus Fee. A summary of the issues faced by the Monitor which led to the repudiation of the Sinclair Range Engagement Agreement, and discussed further in the Monitor’s Fifth Report are detailed below:
 - a) when the Monitor’s Expanded Powers began, the Monitor noticed that communications with Sinclair Range had largely stopped. The Monitor had requested the assistance of Sinclair Range to provide Bookkeeping Services and proposed to pay Sinclair Range the Bookkeeping Services Fees that were accrued (invoice 1593 in the Fee Reconciliation) given

what appeared to be limited costs for Sinclair Range to maintain Bookkeeping Services and the administrative ease of doing so;

- b) in response, Sinclair Range advised the Monitor that only a portion of the Bookkeeping Services were included in the interim management mandate while other parts fell under the financing mandate, which was terminated by Sinclair Range on May 19, 2026;
- c) it appeared to the Monitor that Sinclair Range was not prepared to provide the full range of Bookkeeping Services required without the implied condition that all fees self-assessed as payable by Sinclair Range (including financing fees) were to be paid. Given the scope of services to be provided by Sinclair Range and the limited cash flow, the Monitor communicated to Sinclair Range its intention to perform these duties internally as it believed it could perform the required duties at minimal cost;
- d) to facilitate the change in role, and due to timing constraints, the Monitor requested Sinclair Range's assistance with facilitating payments solely for the week ending May 29, 2026, at a fee to be proposed by Sinclair Range. Further, the Monitor requested copies of certain books, records, or other accounting information pertaining to Sirona to be provided. The Monitor received no response from Sinclair Range and was forced to take alternative measures to facilitate payments and obtain access to the Companies' cash, bank accounts and accounting records;
- e) on June 4, 2026, Sinclair Range send a notice of default to the Monitor in which Sinclair Range demanded immediate payment of amounts Sinclair Range believed were owed to it by Sirona Pharma. Sinclair Range acknowledged the Monitor's request for the Sirona Documents and Records and appeared to indicate that its return of Sirona Documents and Records would be conditional upon the Monitor making payment to Sinclair Range; and
- f) the factors detailed above largely lead to the Monitor advising Sinclair Range on June 15, 2026, of the repudiation of the Sinclair Range Engagement Agreement.

- 51. Further, in agreement with Sinclair Range, the proposed final distribution (as discussed later in this Sixth Monitor's Report) to Sinclair Range in the amount of \$21,235.30 has been determined to be fair compensation for any unpaid invoices to Sinclair Range with Sinclair Range agreeing to make no claim for the Transaction Bonus Fee.
- 52. The Monitor takes the position that Boersma is not entitled to any portion of the Transaction Bonus Fee due, without limitation, to the fact that the CCAA Applicants' engagement was with Sinclair Range pursuant to the terms of Sinclair Range Engagement Agreement, Sinclair Range is in a

position to agree that it has no entitlement to, or to waive its entitlement to, the Transaction Bonus Fee.

FEES AND EXPENSES OF THE MONITOR AND ITS COUNSEL

53. The Monitor is requesting that this Honourable Court approve the fees and expenses of the Monitor since the onset of these CCAA Proceedings up to and including September 3, 2026. Set out in **Schedule "C"** is the Affidavit of Fees detailing the fees of the Monitor and its counsel.
54. Using the standard rates of the Monitor and after applying a courtesy discount of \$25,580.00 and a retainer adjustment of \$6,470.44, the total fees and expenses of the Monitor to September 3, 2026, are \$407,437.96 (including GST).
55. Of the amount above, the Monitor's out-of-pocket expenses to September 3, 2026, have totaled \$20,422.47 (including GST) which are predominantly related to postage, mileage, and advertising.
56. The Monitor is requesting that this Honourable Court approve the fees and expenses of its counsel up to and including September 10, 2026, totaling \$298,685.68 (including GST). Details of the fees and expenses of the Monitor's counsel are also included in **Schedule "C"**.
57. The Monitor notes that due to taxes, there was an adjustment to the final SISP Costs reported in the Supplement to the Monitor's Fifth Report. The Adjusted SISP Costs total \$7,545.17.
58. As discussed elsewhere in this Monitor's Sixth Report, the Monitor proposes a Fee Holdback in the amount of \$130,000.00 (the "**Fee Holdback**") for future fees and expenses to finalize the administration of these proceedings. The proposed Fee Holdback is comprised of the amounts of \$50,000.00, \$70,000.00, and \$10,000.00, payable to the credit of the actual professional costs ultimately incurred by the Monitor, the Monitor's counsel, and counsel to the CCAA Applicants, respectively. Monitor believes the fee holdback is reasonable given the steps still involved in the administration of the CCAA including, but not limited to:
 - a) time already incurred and not reflected in the above;
 - b) the costs of the present Application of the Monitor;
 - c) administrative costs make distributions to various parties and finalization of the estate;
 - d) the completion of any compliance reporting that may be required; and
 - e) any other complications that may arise.

59. It is the respectful opinion of the Monitor that its fees and expenses and the fees and expenses of its counsel as outlined herein are appropriate, fair and reasonable in these circumstances given the complexities involved in these CCAA Proceedings, and as such, should be approved by the Court.

CASH FLOW AND PROPOSED DISTRIBUTION TO CHARGE BENEFICIARIES

60. Attached as **Schedule "D"** to this report is a copy of the Companies cash flow statement up to and including September 10, 2026, and estimates for further cash flows expected in the near future to determine the estimated cash available to distribute. The Monitor has provided explanatory notes for certain items outlined in **Schedule "D"**, where it felt further explanation or details were merited.
61. As noted in **Schedule "D"**, after considering the receipts and disbursements to September 10, 2026, and estimates for future cash flows, there remains an estimated \$1,108,241.63 in the Monitor's trust account for distribution.
62. A holdback for estimated future costs and disbursements of the CCAA Applicants (the **"Disbursements Holdback"**) totalling \$11,657.44. The value of the Disbursements Holdback is based on the following estimates:
- a) an amount of \$491.82 for cheques issued and outstanding;
 - b) an estimate of \$1,299.37 for CRO fees incurred and not yet invoiced, including but not limited to attendance at this application. The Monitor notes that this estimate is equal to the remaining funds held by the CRO from a retainer provided in accordance with the Northern Lights CRO Engagement Agreement;
 - c) an estimated \$1,000.00 for any bank charges which, as of September 10, 2026, had yet to be reflected in the Monitor's trust account;
 - d) an estimated \$3,500.00 for any fees or penalties that may arise as a result of the CRA post-CCAA trust exam. This reserve was determined by the Monitor by calculating the average source deductions per pay period throughout the CCAA period;
 - e) a \$5,000.00 estimate for any other costs that may arise which cannot be reasonably estimated by the Monitor; and
 - f) offset by a net increase of \$366.25, representing the difference between the source deduction payment made by the Companies to Sinclair Range for remittance to the CRA and the amount ultimately determined by the Monitor to be owing to the CRA (subject to the

results of the CRA trust exam). As the original cheque was not cashed, Sinclair Range and the Monitor agreed that Sinclair Range would pay \$6,982.48 to the Monitor for remittance to the CRA. The Monitor determined an amount of \$6,616.23 (subject to the results of the CRA trust exam) is owed to the CRA, resulting in the net increase of \$366.25.

63. It is the Monitor's respectful opinion that the cash flows incurred by the Companies throughout the CCAA Proceedings have been reasonable, in particular, since the Monitor's Expanded Powers.
64. As the proceeds generated from the Subscription Agreement are sufficient to fulfil the Charges in these CCAA Proceedings with limited additional funds available for distribution. As such, the Monitor has not implemented a formal claims process. Instead, on or around September 3, 2026, the Monitor requested updated details of amounts owed to parties covered under the Administration Charge.
65. **Schedule "C"** details the estimated cash available to distribute, including amounts owed under the various Charges in these CCAA Proceedings and accruals to close. A summary has been included below in order of priority:
- a) SISP Expenses: \$7,545.17;
 - b) Administration Charge with a maximum amount of \$1,050,000.00:
 - i. Monitor: total \$262,838.07 which consists of \$212,838.07 for unpaid fees and expenses invoiced to September 3, 2026, and a \$50,000.00 accrual to close;
 - ii. Monitor's counsel: total \$297,594.01 which consists of \$227,591.01 for unpaid fees and expenses invoiced to September 10, 2026, and a \$70,000.00 accrual to close;
 - iii. CCAA Applicants' counsel: total \$351,853.71 which consists of \$341,853.71 for unpaid fees and expenses as of September 11, 2026, and a \$10,000.00 accrual to close; and
 - iv. Sinclair Range: \$21,235.30 for invoices outstanding;
 - v. Boersma Expense Reimbursement amount of \$1,899.53; and
 - c) KERP of \$30,000.00 representing the amounts owed to certain former employees of Sirona Pharma.
66. Regarding the amounts secured by the Administration Charge, the Monitor notes that if the claims of Boersma are included, the total value of claims potentially secured by the Administration Charge will significantly exceed the \$1,050,000.00 value of the Administration Charge. The Monitor takes

the position that Boersma is only entitled to the Boersma Expense Reimbursement amount of \$1,899.53. Should this Honourable Court agree with the Monitor that Boersma maintains no further claims against the Administration Charge for any other amounts beyond the Boersma Expense Reimbursement, the value of claims secured by the Administration Charge, inclusive of proposed Fee Holdback, equal \$935,420.62.

67. Regarding the KERP Charge, the Monitor interprets the terms of the KERP as providing that only three employees of Sirona Pharma, namely Brian Chaisson, Emlyn Ashe, and Marcus Chaison, (collectively, the “**KERP Beneficiaries**”) have all satisfied applicable Vesting Criteria (as defined in the KERP). The Vesting Criteria set out in the KERP provide that each of the three KERP Beneficiaries each become entitled to payment of \$10,000.00 upon the successful reinstatement of Sirona Pharma’s Health Canada license, which occurred in May of 2026. None of the three KERP Beneficiaries have previously received payment of these \$10,000.00 amounts, or any portion thereof. The Monitor has determined that each of the three KERP Beneficiaries appear to be entitled payment of their respective \$10,000.00 entitlements under the KERP, thus exhausting the full \$30,000.00 value of the KERP Charge.
68. The Monitor is not aware of any claims made against the current or former directors of Sirona Pharma that may give rise to potential claims against the D&O Charge (as defined in the ARIO). Further, the majority of such possible claims would have been released pursuant to the provisions of the RVO. Accordingly, the Monitor does not anticipate any claim made against the D&O Charge and is not contemplating any allocation of funds towards the D&O Charge.
69. In light of the above, and upon the basis of legal opinions provided to the Monitor by its legal counsel, the Monitor proposes the following distributions to the beneficiaries of the Court ordered charges granted by this Honourable Court in these proceedings, paid in the following Order of priority:
 - a) payment to the Monitor for SISP Expenses in the amount of \$7,545.17;
 - b) payment to the Administration Charge beneficiaries as follows:
 - i. to the Monitor, \$212,838.07;
 - ii. to the Monitor’s counsel, \$227,594.01;
 - iii. to CCAA Applicants’ counsel, \$341,853.71;
 - iv. to Sinclair Range, \$21,235.30;

- v. to Mr. Boersma, \$1,899.53;
 - vi. to the Monitor, a holdback in the amount of \$130,000.00;
 - vii. to the Monitor, a holdback in the amount of \$11,657.44 representing the Disbursements Holdback; and
- c) payment of KERP in the amount of \$30,000.00 to the KERP Beneficiaries in accordance with the KERP agreement.
70. The Fee Holdback is necessary and appropriate, and is properly secured by the Administration Charge, as the Monitor anticipates that the future fees incurred by restructuring professionals to finalize the administration of these proceedings will be roughly \$130,000.00, given the steps still involved in the administration of these CCAA Proceedings, including but not limited to:
- a) time already incurred and not reflected in the above;
 - b) the costs of the present Application of the Monitor;
 - c) administrative costs make distributions to various parties and finalization of the estate;
 - d) potential receipt of GST tax credits from the CRA and the completion of any compliance reporting that may be required; and
 - e) any other complications that may arise.
71. The Monitor is of the view that the Proposed Distributions accord with the creditors' respective priority entitlements and respectfully requests that the Court approve the Proposed Distributions.

REMAINING FUNDS

72. Any remaining funds after the Proposed Distribution, the Disbursements Holdback and any future funds that may be received will be referred to as "**Remaining Funds**".
73. As detailed above and in **Schedule "D"** after the Charges are satisfied the Monitor estimates the Remaining Funds to range from \$20,696.46 to \$135,275.84 (excluding any potential GST refund).
74. The Remaining Funds are considerably lower than the combined claims of secured and other priority creditors in these CCAA Proceeding.
75. The Monitor's counsel provided certain security opinions in relation to the validity, enforceability, and priority of each secured creditor's claim for which the Monitor has received security

documentation, subject to the customary assumptions and qualifications contained in opinions of this nature.

76. The security opinions received opined that following secured creditors have may valid and enforceable security interests in the respective property and detail complications in determining the priority of some of the secured creditors:
- a) Canada Revenue Agency for deemed trust claims owing on source deductions. Given the lack of historical financial records, the date which the deemed trust claim for source deductions owing arose has not been determined;
 - b) Connex Mortgage for which may rank in priority to the Canada Revenue Agency depending on when the deemed trust claim for source deductions arose;
 - c) Yellowhead County Municipality for property taxes owing which will rank in priority to the Conex Mortgage on sale proceeds attributable to the lands sold, but subordinate to any deemed trust claim of the Canada Revenue Agency for source deductions; and
 - d) Certain former employees of Sirona Pharma, whose claims are maintained and perfected pursuant to writs formerly registered against the assets by Government of Alberta - Employment Standards, Collections Unit.
77. The Monitor believes the estate has insufficient funds for the Monitor and its counsel to administer a claims process and conduct a comprehensive priority analysis among the secured creditors. The associated professional fees would significantly reduce recoveries for creditors asserting competing priorities while providing limited benefit to the estate. Accordingly, the Monitor proposes remitting the Remaining Funds to this Honourable Court to be held pending an agreement among the affected parties regarding their allocation or the further Order of this Honourable Court.

PROPOSED DISCHARGE OF THE CRO

78. The Monitor understands that the mandate of the CRO has been substantially completed and that the services of the CRO are no longer required in connection with these CCAA proceedings. The Monitor is satisfied that appropriate reserves have been established for any remaining matters and supports the discharge of the CRO, together with such releases and protections as are provided for in the proposed order.

REMAINING ACTIVITIES OF THE MONITOR

79. To conclude these CCAA proceedings, the Monitor advises that the following actions/matters need to be resolved (the “**Remaining Activities**”). It is the Monitor's intention to address these matters following the Court's approval of the items noted in this report. These matters include:
- a) completion of the Proposed Distribution and remittance of Remaining Funds, as discussed above;
 - b) completion of the post-CCAA CRA trust exam and the remittance of any amounts owing as a result; closing the estate bank accounts and filing any ancillary documents with regulatory bodies as required under the CCAA, the Court, CRA, and/or the Superintendent of Bankruptcy; and
 - c) any other activities that may be required.

PROPOSED TERMINATION OF THE CCAA AND DISCHARGE OF THE MONITOR

80. Upon completion of the Remaining Activities, the Sirona Pharma et al. CCAA proceedings will be materially complete, and there will be no further administrative matters remaining for the Companies or the Monitor.
81. Accordingly, the role of the Monitor will be complete and as such, the Monitor is requesting its discharge upon:
- a) completion of the Remaining Activities; and
 - b) filing of a termination certificate by the Monitor (the “**Termination Certificate**”).
82. Should any funds be received for GST credits, after the Termination Certificate is filed, the Monitor will direct any funds received to the Honourable Court in accordance with the Monitor's treatment of Remaining Funds.
83. The proposed Termination Certificate is attached as Schedule “A” to the Monitor's Application for discharge and termination order (the “**Conditional Termination Order**”).

REVISED STAY EXTENSION

84. Pursuant to the October 31 Stay Extension Order, the Applicants were granted a stay extension up to and including October 31, 2026. The Monitor is requesting a Revised Stay Extension to December 31, 2026, to address the Remaining Activities and conclude these CCAA Proceedings.

85. The Monitor does not believe that any creditor will be materially prejudiced if an extension of the Stay Period to the Revised Stay Extension Date is granted. These proceedings may terminate earlier than the Revised Stay Extension Date by way of Monitor's filing and service of the Termination Certificate.

RECOMMENDATIONS

86. Based on the matters outlined in this Monitor's Sixth Report, the Monitor respectfully requests that this Honourable Court grant an order or orders approving:
- a) the activities of the Monitor as outlined herein;
 - b) the fees and expenses of the Monitor and its counsel;
 - c) the Proposed Distribution;
 - d) the remittance of Remaining Funds to this Honourable Court to be held in trust;
 - e) the discharge of the CRO;
 - f) discharge of the Monitor of the Applicants and terminates these CCAA proceedings upon the Monitor filing the Monitor's Termination Certificate with the Clerk of the Court evidencing that all steps required to complete these CCAA proceedings have been completed as required;
 - g) an extension of the Revised Stay Period to December 31, 2026; and
 - h) such further relief, advice and direction that this Honourable Court considers just and warranted in the circumstances.

Dated at Edmonton, this 21st day of September 2026.

ERNST & YOUNG INC.

Licensed Insolvency Trustee

acting solely in its capacity as the Monitor of

SuneRa Acreage Holdings Inc.

**Acreage Development Corp., Sirona Farms Inc.,
and 2834015 Alberta Ltd.**

and not in its personal or corporate capacity



Matt McCulloch, CPA, CA, CIRP, LIT
Senior Vice President, Ernst & Young Inc.



Karen Zahacy CPA, CIRP, LIT
Director, Ernst & Young Inc.

SCHEDULE "A"

February 4, 2026

Via Email:

jeanchiasson@icloud.com
jagdeepgupta@gmail.com

Mr. Jean Chiasson
President & CEO Sirona Pharma Inc.

Dear Jean:

Re: Amendment to Engagement Letter

This Amendment (the "Amendment") to the Engagement Letter dated October 14, 2025, and signed on October 16, 2025 (the "Agreement"), is made and entered into as of the date hereof by and between Sirona Pharma Inc. (the "Company") and Sinclair Range Inc. ("Sinclair Range").

Recitals

WHEREAS, the Company and Sinclair Range entered into the Agreement for financing and interim management services;

AND WHEREAS, the Company has engaged Sinclair Range for both the Interim Management and Financing Mandates as defined in the Agreement;

AND WHEREAS, the parties wish to modify certain terms and conditions of the Agreement;

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties agree to amend the Agreement as follows:

Specific Amendments

The Agreement is amended as follows:

Amendment 1 (Personnel and Title Change): In the section titled "Interim Management", the Chief Restructuring Advisor role is updated in personnel and title.

The updated text in the bullet points on pages 3 and 4 shall read: " "Chief Restructuring Officer" – oversight of operational and financial aspects of the business (David Blair);"

Amendment 2 (Fee Structure Update): The "Fees" subsection under "Interim Management" on page 4 is updated to reflect the new combined fee structure and titles and acknowledge prior payments.

The parties acknowledge that the initial fees of \$25,000 for both the Chief Restructuring Officer (formerly Advisor) and Strategy and Regulatory Compliance Advisor roles have previously been charged as of the date of this Amendment.

The active fee structure from the effective date of this Amendment is:

- "Chief Restructuring Officer (CRO) and Regulatory Compliance: A fixed monthly work fee of \$15,000, earned and payable in advance; all services related to the former "Strategy and Regulatory Compliance Advisor" role are now included in this fee structure."
- The specific line item for "Strategy and Regulatory Compliance Advisor" with the \$10,000 fee is hereby removed from the agreement.

Amendment 3 (Indemnification Update): The "Indemnification" section on page 5 is amended to update the list of indemnified individuals and their associated companies.

The phrase "Grand Arc Bend Inc. (Gord Boersma)" is deleted and replaced by "Northern Lights Management Corporation (David Blair)" as an indemnified party.

Affirmation of Agreement

Except as specifically amended by this Amendment, all other terms, conditions, and provisions of the original Engagement Letter shall remain in full force and effect. The parties agree that the Agreement, as amended by this Amendment, represents the entire agreement between the parties with respect to the subject matter hereof.


Execution

The parties have executed this Amendment as of the date first written above.

Sirona Pharma Inc.

Sinclair Range Inc.

Signature: 

Signature: 

Name: Jean Chiasson

Name: Scott Sinclair

Title: President & CEO

Title: President

Date: February 5, 2026

Date: February 5, 2026

Amendment to Sirona Pharma Engagement Letter - Februrary 3 2026

Final Audit Report

2026-02-05

Created:	2026-02-05
By:	Ali Cassels (acassels@mltaikins.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA5zk53Gcto0fb4ITUSnikUlWBXyTixxeo

"Amendment to Sirona Pharma Engagement Letter - Februrary 3 2026" History

-  Document created by Ali Cassels (acassels@mltaikins.com)
2026-02-05 - 8:21:11 PM GMT- IP address: 207.34.87.170
-  Document emailed to jeanchiasson@icloud.com for signature
2026-02-05 - 8:21:49 PM GMT
-  Email viewed by jeanchiasson@icloud.com
2026-02-05 - 9:14:38 PM GMT- IP address: 104.28.116.18
-  Signer jeanchiasson@icloud.com entered name at signing as Jean Chiasson
2026-02-05 - 9:19:19 PM GMT- IP address: 104.28.124.14
-  Document e-signed by Jean Chiasson (jeanchiasson@icloud.com)
Signature Date: 2026-02-05 - 9:19:21 PM GMT - Time Source: server- IP address: 104.28.124.14
-  Agreement completed.
2026-02-05 - 9:19:21 PM GMT

SCHEDULE “B”

Monitor's Sixth Report
Schedule "B"

Invoice Number	Invoice Date	Category	Term	Amount Including GST	Amount Paid and Payee			Unpaid Balance (Overpaid)
					Sinclair Range	Grand Arc	Norther Lights	
1531	01-Dec-25	Financing	Nov 16 - Dec 15	15,750.00		15,750.00		-
1531	01-Dec-25	Success Fee Initial DIP		43,312.50	43,312.50			-
1531	01-Dec-25	Expense		1,583.22		1,583.22		-
1532	01-Dec-25	CRO	Nov 21 - Dec 21	26,250.00		26,250.00		-
1532	01-Dec-25	Strategy and compliance offic	Nov 21 - Dec 21	26,250.00	26,250.00			-
1532	01-Dec-25	Expense		1,272.12		1,272.12		-
1533	01-Dec-25	Bookkeeping/Controller	Nov 21 - Dec 21	5,250.00	5,250.00			-
1536	05-Dec-25	Financing	October 16 - Nov 16	1,250.00		1,250.00		-
1542	22-Dec-25	Bookkeeping/Controller	Dec 22 - Jan 21	5,250.00	5,250.00			-
1543	22-Dec-25	CRO	Dec 22 - Jan 21	15,750.00	15,750.00			-
1543	22-Dec-25	Strategy and compliance offic	Dec 22 - Jan 21	10,500.00	10,500.00			-
1543	22-Dec-25	Expense		2,601.34	2,601.34			-
1543	22-Dec-25	Expense		2,041.00	2,041.00			-
1544	22-Dec-25	Financing	Dec 16 - Jan 15	15,750.00	11,835.11	3,914.89		-
1552	20-Jan-26	Financing	Jan 16 - Feb 15	15,750.00	6,867.99	8,944.48		62.47
1550	22-Jan-26	Bookkeeping/Controller	Jan 22 - Feb 21	5,250.00	5,250.00			-
1551	22-Jan-26	CRO	Jan 22 - Feb 21	15,750.00	15,750.00			-
1551	22-Jan-26	Strategy and compliance offic	Jan 22 - Feb 21	10,500.00	10,500.00			-
1551	22-Jan-26	Expense		2,041.00	2,041.00			-
1562	23-Feb-26	Financing	Feb 16 - Mar 15	15,750.00	15,750.00			-
1563	23-Feb-26	Bookkeeping/Controller	Feb 22 - Mar 21	5,250.00	5,250.00			-
1564	23-Feb-26	CRO	Feb 22 - Mar 21	15,750.00			15,750.00	-
1567	27-Feb-26	CRO	Feb 6 - Feb 22	4,200.00			4,200.00	-
1572	23-Mar-26	Financing	Mar 16 - Apr 15	15,750.00	15,750.00			-
1573	23-Mar-26	CRO	Mar 22 - April 21	15,750.00			15,750.00	-
1574	23-Mar-26	Bookkeeping/Controller	Mar 22 - April 21	5,250.00	5,250.00			-
1583	22-Apr-26	Bookkeeping/Controller	Apr 22 - May 21	5,250.00	5,250.00			-
1584	22-Apr-26	CRO	Apr 22 - May 21	15,750.00			15,750.00	-
1585	22-Apr-26	Financing	Apr 16 - May 15	15,750.00	15,750.00			-
1591	19-May-26	Financing	May 16 - June 15	15,750.00				15,750.00
1592	19-May-26	CRO	May 22 - June 22	15,750.00				15,750.00
1593	19-May-26	Bookkeeping/Controller	May 22 - June 22	5,250.00				5,250.00
1593	19-May-26	Expense		235.30				235.30
Total				373,536.48	\$226,198.94	\$58,964.71	\$51,450.00	36,922.83
Total Paid				336,613.65				
Proposed Payment				21,235.30				
Adjusted Total/ Amount to be Paid				357,848.95				

SCHEDULE "C"

COURT FILE NUMBER **2503 23802**

COURT COURT OF KING'S BENCH OF ALBERTA

JUDICIAL CENTRE EDMONTON

APPLICANTS IN THE MATTER OF THE COMPANIES'
CREDITORS ARRANGEMENT ACT,
R.S.C. 1985, C. C-36, AS AMENDED

Clerk's Stamp

AND IN THE MATTER OF A PLAN OF
COMPROMISE OR ARRANGEMENT OF
SUNERA ACREAGE HOLDINGS INC.,
ACREAGE DEVELOPMENT CORP.,
SIRONA FARMS INC., and 2834015
ALBERTA LTD.

DOCUMENT **AFFIDAVIT OF FEES**

ADDRESS FOR SERVICE
AND
CONTACT INFORMATION OF
PARTY FILING THIS
DOCUMENT McLennan Ross LLP
600, McLennan Ross Building
12220 Stony Plain Rd.
Edmonton, Alberta T5N 3Y4
Phone: 780.482.9153 / 403.303.2934

Lawyer's Name: Ryan Trainer
 Kevin Hoy
 ryan.trainer@mross.com
Lawyer's Email: kevin.hoy@mross.com

AFFIDAVIT OF KAREN ZAHACY

Sworn on September 17, 2026

I, Karen Zahacy, of the City of Edmonton, of the Province of Alberta, SWEAR AND SAY THAT:

1. I am a Licensed Insolvency Trustee and Director of Ernst & Young Inc. ("EY"). EY was appointed as the Court-appointed Monitor over Sunera Acreage Holdings Inc., Acreage Development Corp., Sirona Farms Inc., and 2834015 Alberta Ltd. (the "**Companies**") pursuant to the Initial Order granted by Alberta Court of Kings Bench the Companies gained protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, C. C-36, As Amended (the "**CCAA**") on November 21, 2025 (the "**Initial Order**"). Pursuant to the Initial Order, Ernst & Young Inc. was appointed Monitor of the Companies (the "Monitor"). An Amended and Restated Initial Order ("ARIO") was subsequently granted on November 28, 2025, which was confirmed the continuation of the CCAA and the appointment of the Monitor. Further, pursuant to an Order of the Court dated May 20, 2026, the Monitor has been granted enhanced powers and oversight authority in respect of certain matters relating to the Companies' ongoing restructuring.

2. As such, based upon my personal knowledge regarding the matters sworn to herein, and based upon my review of the records kept in the ordinary course of business, I have personal knowledge of the matters and facts hereinafter sworn to, except where stated to be based on information and belief, in which case, I verily believe the same to be true.
3. I am authorized to swear this Affidavit on behalf of EY (hereinafter referred to as, the "**Monitor**"), in its capacity as the Monitor over the Companies.
4. This Affidavit is made in support of an application by the Monitor for an Order for, among other things, the approval of fees and disbursements of the Monitor since the onset of these CCAA Proceedings to September 3, 2026, (the "**Fee Period**"). This affidavit is filed in conjunction with the Monitor's Sixth Report, dated September 21, 2026.

Monitor's Fees

5. The total amount of the fees and disbursements claimed by the Monitor, for the Fee Period, is \$407,437.96 including GST and expenses, after a courtesy discount of \$25,580.00 and a retainer adjustment of \$6,470.44. In addition, SISP Expenses totaled \$7,545.17.
6. Attached and marked as **Exhibit "A"** to this, my Affidavit, is a copy of the invoices rendered by the Monitor during the Fee Period, which outlines the fees, disbursements (if any), and total fees charged under each invoice (the "**Accounts**") and a schedule of the invoices summarizing the billing rates of each individual of the Monitor that rendered services in connection with the CCAA Proceedings. The detailed time records have been excluded from this Affidavit as a number of time entries contain privileged commentary in relation to the CCAA Proceedings. However, should the Court or another stakeholder request to review the detailed time records, the Monitor will provide detailed time records in a confidential supplement or alternatively, redacted time records upon request.
7. The Account and summary chart disclose the name of each person who rendered services, the total hours of such individual, the rate charged, and the total charges for fees, disbursements, and taxes.
8. I have reviewed the Monitor's Reports and confirm that, to the best of my knowledge, the work detailed therein was carried out by the Monitor and such work was necessary to the Monitor in carrying out its obligations pursuant to these CCAA Proceedings.
9. I have reviewed the Accounts and verily believe, and confirm to the best of my knowledge, that the hourly rates charged are reasonable and comparable to the hourly rates charged for similar services by other restructuring firms within the City of Edmonton of equivalent competence and expertise in the insolvency area.

Monitor's Counsel's Fees

10. EY retained McLennan Ross LLP ("**MR**") as counsel to the Monitor in the within these CCAA Proceedings.

11. I have reviewed the invoices of MR rendered from the inception of these CCAA Proceedings to September 10, 2026, and I am satisfied that the services have been undertaken by MR at the request of the Monitor and that the fees and disbursements of MR are reasonable. Copies of MR invoices, totalling \$ 298,685.68 (including GST) are attached as **Exhibit "B"**.

SWORN (OR AFFIRMED) BEFORE ME at)
Edmonton, Alberta, this 17th day of September,)
2026.)




Commissioner for Oaths in and for the Province
of Alberta)

Trina Marie Sorbara
Commissioner for Oaths

(Print Name and Province of Alberta
Expiry/Lawyer/Student-At-Law) Expiry Date: February 27, 2029.



(Signature)



(Print Name)

This is Exhibit "A" to the Affidavit of
Karen Zahday sworn

before me this 17 day of September 20 26

Exhibit "A"


A Commissioner for Oaths in and for the
Province of Alberta

Trina Marie Sorbara
Commissioner for Oaths
Province of Alberta
Expiry Date: February 27, 2029.



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013250

Please include this number with payment

Invoice Date: November 26, 2025

Due Date: Upon receipt

Client No.: 0013950694

Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from November 4 to November 21, 2025 in connection with the Engagement Letter dated November 4, 2025 in relation to the CCAA proceedings of Sirona Pharma Inc. et al. The fees rendered included, but are not limited to, the review, analysis, and reporting of financial information, affidavits and legal materials, discussions with Management, the compilation of pre-filing materials for the Initial Order application dated November 21, 2025 and attending court for the application.

	Net	Tax	Rate	Tax Amount	CAD Total
Fee	23,159.18	GST	5 %	1,157.96	24,317.14
	23,159.18			1,157.96	24,317.14
Invoice summary	23,159.18				
Tax: 5% GST				1,157.96	
Total:	23,159.18			1,157.96	24,317.14

Original invoice : CA12C500012964

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013251
Please include this number with payment

Invoice Date: December 08, 2025
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from November 22 to December 3, 2025, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et. al. The fees rendered included, but are not limited to, the review, analysis, and reporting of financial information, affidavits and legal materials, discussions with Management, the compilation of the Monitor's first report and attending court on November 28, 2025.

	Net	Tax	Rate	Tax Amount	CAD Total
Fees:	24,096.50				
Less: Discount:	-2,040.00				
Total Fees:	22,056.50	GST	5 %	1,102.83	23,159.33
	22,056.50			1,102.83	23,159.33
Invoice summary	22,056.50				
Tax:	5% GST			1,102.83	
Total:	22,056.50			1,102.83	23,159.33

Original Invoice : CA12C500012965

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013055

Please include this number with payment

Invoice Date: January 07, 2026

Due Date: Upon receipt

Client No.: 0013950694

Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from December 4 to December 22, 2025, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et. al. The fees rendered included, but are not limited to, the review, analysis, and reporting of financial information, affidavits and legal materials, discussions with Management, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fees:	24,642.50	GST	5 %	1,232.13	25,874.63
Advertising Expenses:	19,675.28	GST	5 %	983.76	20,659.04
	44,317.78			2,215.89	46,533.67
Invoice summary	44,317.78				
Tax:		5% GST		2,215.89	
Total:	44,317.78			2,215.89	46,533.67

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013150
Please include this number with payment

Invoice Date: January 29, 2026
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from December 23, 2025 to January 23, 2026, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et. al. The fees rendered include, but are not limited to, the review, analysis, and reporting of financial information, affidavits and legal materials, discussions with Management, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	<u>CAD</u> Total
Fees:	30,110.00	GST	5 %	1,505.50	31,615.50
	30,110.00			1,505.50	31,615.50
Invoice summary	30,110.00				
Tax:		5% GST		1,505.50	
Total:	30,110.00			1,505.50	31,615.50

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013203

Please include this number with payment

Invoice Date: February 10, 2026

Due Date: Upon receipt

Client No.: 0013950694

Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from January 24 to February 6, 2026, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et al. The fees rendered include, but are not limited to, the review, analysis, and reporting of financial information, affidavits, legal materials, discussions with Management, drafting of the Monitor's report to court, attending court, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fee	37,822.50	GST	5 %	1,891.13	39,713.63
	37,822.50			1,891.13	39,713.63
Invoice summary	37,822.50				
Tax: 5% GST				1,891.13	
Total:	37,822.50			1,891.13	39,713.63

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013362

Please include this number with payment

Invoice Date: March 11, 2026

Due Date: Upon receipt

Client No.: 0013950694

Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from February 7 to March 6, 2026, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et al. The fees rendered include, but are not limited to, the review, analysis, and reporting of financial information, affidavits, legal materials, discussions with Management, drafting of the Monitor's report to court, attending court, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fee	25,962.50	GST	5 %	1,298.13	27,260.63
	25,962.50			1,298.13	27,260.63
Invoice summary	25,962.50				
Tax: 5% GST				1,298.13	
Total:	25,962.50			1,298.13	27,260.63

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013489
Please include this number with payment

Invoice Date: April 20, 2026
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from March 7 to April 10, 2026, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et al. The fees rendered include, but are not limited to, the review, analysis, and reporting of financial information, affidavits, legal materials, discussions with Management, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fees:	16,973.50	GST	5 %	848.68	17,822.18
Expenses:	747.18	GST	5 %	37.36	784.54
	17,720.68			886.04	18,606.72
Invoice summary	17,720.68				
Tax: 5% GST				886.04	
Total:	17,720.68			886.04	18,606.72

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013595
Please include this number with payment

Invoice Date: May 11, 2026
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for payment instructions.

For advisory services rendered from February 9, 2026, to April 10, 2026, that were not billed previously, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et. al. The fees rendered include, but are not limited to, the review, analysis, and reporting of financial information, affidavits, legal materials, discussions with Management, drafting of the Monitor's report to court, attending court, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fees:	50,275.00				
Less: Courtesy Discount:	-23,000.00				
Total Fees:	27,275.00	GST	5 %	1,363.75	28,638.75
	27,275.00			1,363.75	28,638.75
Invoice summary	27,275.00				
Tax: 5% GST				1,363.75	
Total:	27,275.00			1,363.75	28,638.75

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500013602
Please include this number with payment

Invoice Date: May 12, 2026
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For advisory services rendered from April 13, 2026, to May 8, 2026, in connection with the Engagement Letter dated November 4, 2025, in relation to the CCAA proceedings of Sirona Pharma Inc. et. al. The fees rendered include, but are not limited to, the review, analysis, and reporting of financial information, affidavits, legal materials, discussions with Management, drafting of the Monitor's report to court, attending court, and addressing correspondence from various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fee:	26,176.00				
Less- Discount:	-540.00				
Total Fee:	25,636.00	GST	5 %	1,281.80	26,917.80
	25,636.00			1,281.80	26,917.80
Invoice summary	25,636.00				
Tax:		5% GST		1,281.80	
Total:	25,636.00			1,281.80	26,917.80

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500014090

Please include this number with payment

Invoice Date: September 11, 2026
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

Advisory services rendered from May 9, 2026 to September 3, 2026, pursuant to the Engagement Letter dated November 4, 2025, in connection with the CCAA proceedings of Sirona Pharma Inc. et al. Services provided included, but were not limited to, the review, analysis, and reporting of financial information; review of affidavits and legal materials; discussions with Management; execution of SISP procedures; performance of duties associated with the Monitor's enhanced powers; preparation of court reports; attendance at court proceedings; and correspondence with various stakeholders.

	Net	Tax	Rate	Tax Amount	CAD Total
Fees:	133,976.00	GST	5 %	6,698.80	140,674.80
	133,976.00			6,698.80	140,674.80
Invoice summary	133,976.00				
Tax: 5% GST				6,698.80	
Total:	133,976.00			6,698.80	140,674.80

A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498



Ernst & Young Inc.
Edmonton, AB

Invoice

Sirona Pharma Inc.
14129 East Bank Rd
Yellowhead County, AB T7E 3Z4
Canada

Invoice No.: CA12C500014098
Please include this number with payment

Invoice Date: September 14, 2026
Due Date: Upon receipt
Client No.: 0013950694
Engagement No.: E-69520476

Please see last page of the invoice for
payment instructions.

For costs incurred by the Monitor in relation to the CCAA of Sirona Pharma Inc. et al.

	Net	Tax	Rate	Tax Amount	CAD Total
SISP Costs:	7,185.88	GST	5 %	359.29	7,545.17
	7,185.88			359.29	7,545.17
Invoice summary	7,185.88				
Tax:		5% GST		359.29	
Total:	7,185.88			359.29	7,545.17


A member of Ernst & Young Global

Terms: Payment due upon receipt. Interest is charged at the rate of 12 % per annum on balances unpaid after 30 days from date of invoice. Any disbursements not charged to your account on the date of this invoice will be billed later.
GST/HST: R123425522 **QST:** 1006354498

Sixth Report of the Monitor
Summary of Monitor's Fees

Individual	Rank	Hours	Rate	Total
Chavi Aggarwal	Staff	2.00	295	590.00
Dan Pintaric	Director	5.60	450	2,520.00
Evan MacKinnon	Senior Director	190.3	575	109,422.50
Joe Dodard	Staff	14.40	295	4,248.00
Kaitlyn Benvenuto	Staff	2.70	375	1,012.50
Kaitlyn Benvenuto	Staff	2.80	295	826.00
Karen Zahacy	Director	418.78	450	188,453.12
Karen Zahacy	Director	75.90	425	32,257.50
Madison Jean	Staff	13.50	225	3,037.50
Matt McCulloch	Senior Vice Presiden	67.90	750	50,925.00
Nick DiVincenzo	Staff	6.00	295	1,770.00
Richard Funk	Staff	10.00	295	2,950.00
Robert Ferguson	Consultant	0.40	295	118.00
Trina Sorbara	Paraprofessional	5.20	295	1,534.00
Total				399,664.12
Retainer Adjustment				6,470.44
Courtesy Discount				25,580.00
Net Fees				367,613.68
Expenses (excluding SISP Expenses)				20,422.47
Total Before GST				388,036.15
GST				19,401.81
Total Including GST				407,437.96

Exhibit "B"

This is Exhibit "A" to the Affidavit of
Karen Zahary sworn
before me this 17 day of September 2026

A Commissioner for Oaths in and for the
Province of Alberta

Trina Marie Sorbara
Commissioner for Oaths
Province of Alberta
Expiry Date: February 27, 2029.

McLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: EVAN MACKINNON

Invoice Date: December 2, 2025
Invoice No.: 892670
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

RE: **SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR**

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

	Currency: CAD
Fees	\$17,451.00
Costs (Taxable)	\$144.12
	\$17,595.12
GST	\$879.76
	\$18,474.88
Costs (Non-Taxable)	\$54.68
Total Amount Due	\$18,529.56

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

McLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: KAREN ZAHACY

Invoice Date: January 28, 2026
Invoice No.: 896680
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

RE: **SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR**

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

	Currency: CAD
Fees	\$32,827.00
Costs (Taxable)	<u>\$439.03</u>
	\$33,266.03
GST	<u>\$1,663.30</u>
	\$34,929.33
Costs (Non-Taxable)	<u>\$92.00</u>
Total Amount Due	\$35,021.33

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

McLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: KAREN ZAHACY

Invoice Date: February 9, 2026
Invoice No.: 897599
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

RE: SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

Currency: CAD

Fees	\$16,705.50
GST	\$835.28
Total Amount Due	\$17,540.78

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

McLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: KAREN ZAHACY

Invoice Date: March 12, 2026
Invoice No.: 899743
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

**RE: SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR**

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

Currency: CAD

Fees	\$21,211.00
Costs (Taxable)	\$60.00
	\$21,271.00
GST	\$1,063.55
Total Amount Due	\$22,334.55

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

McLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: KAREN ZAHACY

Invoice Date: April 20, 2026
Invoice No.: 902517
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

RE: **SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR**

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

Currency: CAD

Fees	\$7,687.00
Costs (Taxable)	\$25.54
	\$7,712.54
GST	\$385.63
Total Amount Due	\$8,098.17

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

McLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: KAREN ZAHACY

Invoice Date: July 16, 2026
Invoice No.: 908764
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

RE: **SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR**

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

	Currency: CAD
Fees	\$129,309.00
Costs (Taxable)	\$426.38
	\$129,735.38
GST	\$6,486.77
	\$136,222.15
Costs (Non-Taxable)	\$460.43
Total Amount Due	\$136,682.58

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

MCLENNAN ROSS

LEGAL COUNSEL

ERNST & YOUNG INC.
10423 101 STREET NW, SUITE 1400
EDMONTON, AB T5H 0E7

ATTENTION: KAREN ZAHACY

Invoice Date: September 11, 2026
Invoice No.: 912592
Client No.: 004355
Matter No.: 20254457 RTT

SUMMARY OF ATTACHED ACCOUNT

RE: **SIRONA PHARMA INC., SONIDECH HOLDINGS INC., VAN MAREN FINANCIAL (2019) LTD.,
AND YADEVINDER BHULLAR**

Total fees, other charges, disbursements and tax for professional services rendered, details of which are attached.

	Currency: CAD
Fees	\$57,132.00
Costs (Taxable)	\$225.77
	\$57,357.77
GST	\$2,867.89
	\$60,225.66
Costs (Non-Taxable)	\$253.05
Total Amount Due	\$60,478.71

G.S.T. #R119415172

ALL ACCOUNTS ARE PAYABLE UPON RECEIPT, INTEREST AT THE RATE OF 1.5% PER MONTH (18% PER ANNUM) SHALL BE CHARGED ON ALL ACCOUNTS FROM DATE OF BILLING; HOWEVER, NO INTEREST WILL BE CHARGED ON ACCOUNTS PAID WITHIN 30 DAYS.

SEE REMITTANCE PAGE FOR PAYMENT OPTIONS

Edmonton

600 McLennan Ross Building
12220 Stony Plain Road
Edmonton, AB T5N 3Y4
Telephone 780 482 9200
Facsimile 780 482 9100
Toll-free 800 567 9200

Calgary

1900 Eau Claire Tower
600 – 3rd Avenue SW
Calgary, AB T2P 0G5
Telephone 403 543 9120
Facsimile 403 543 9150
Toll-free 888 543 9120

Yellowknife

301 Nunasi Building
5109 – 48th Street
Yellowknife, NT X1A 1N5
Telephone 867 766 7677
Facsimile 867 766 7678
Toll-free 888 836 6684

mross.com

SCHEDULE “D”

Monitor's Sixth Report
Schedule "D"

Cash Flow to September 10, 2026

	CFS2	CFS3	CFS4+	Total	Note
Cash Flow Week	Actual	Actual	Actual	Actual	
Week Beginning	21-Nov-26	30-Jan-26	25-Apr-26	21-Nov-26	
Week Ending	30-Jan-26	24-Apr-26	10-Sep-26	10-Sep-26	
Operating Receipts					
Cash from Other RBC Accounts			264	264	
Quebec Tax Refund			2,732	2,732	
SISP Deposit			545,000	545,000	Deposits received and returned in connection with the SISP
Proceeds From Sale	-	-	3,949,005	3,949,005	
	-	-	4,497,001	4,497,001	
Disbursements					
Standby facility costs	241,974	261,673	203,889	707,537	
Standby labour	162,417	233,097	49,977	445,491	
Management, sales agent	132,683	126,222	18,610	277,515	
Tax filings	-	-	-	-	
Appraisal	-	-	7,403	7,403	
Restructuring fees	119,010	355,056	74,704	548,770	
Finance fees	68,725	99,094	570	168,389	
Return of SISP Deposit			545,000	545,000	
Sale Cure Costs			134,565	134,565	
Total disbursements	724,810	1,075,141	1,034,718	2,834,669	
Net cash flow	-	724,810 -	1,075,141	3,462,283	1,662,332
Beginning cash	-	100,190	275,049	-	-
DIP Proceeds	825,000	1,250,000	100,000	2,175,000	
DIP Repayment		-	2,717,433 -	2,717,433	
Ending cash	100,190	275,049	1,119,899	1,119,899	
EY Trust account				1,118,599.70	
Retainer CRO (Paid)				1,299.37	
Total Cash				1,119,899.07	
Difference			-	0.00	
Adjustments to Cash Available:					
Outstanding Cheques:					
	Payroll			34.56	
	Elevated Signals			457.26	
CRA Source Deductions Outstanding:					
	Source Receipt from Sinclair Range			6,982.48	Cheque remitted to CRA by Sinclair Range which remained uncashed. Sinclair Range directed the funds to the Monitor for remittance.
	Source Payment to CRA		-	6,616.23	
Estimated Fees/Expenses:					
	CRO			1,299.37	Estimate to close. Represents the remaining retainer held by the CRO
	Bank Charges			1,000.00	Estimate
	CRA Trust Exam			3,500.00	Calculated by EY, the average source deductions throughout the CCAA for one period.
	Other			5,000.00	Estimate
Adjusted Cash Available				1,108,241.63	

Distribution Analysis

Priority Charges

1 SISP Expenses 7,545.17

2 Administration Charge: Max \$1,050,000

Professional Fees

2a Monitor

i	Invoice #	Invoice Date	Invoice Amount	
	CA12C500013489	11-May-26	18,606.72	
	CA12C500013602	12-May-26	26,917.80	
	CA12C500013595	20-Apr-26	26,638.75	
	CA12C500014090	11-Sep-26	140,674.80	
	Total Invoices		212,838.07	
ii	Accrual to close		50,000.00	Estimate
	Total			262,838.07

2b Monitor's Counsel To July 14

ii	Invoice #	Invoice Date	Invoice Amount	
	899743	12-Mar-26	22,334.55	
	90257	20-Apr-26	8,098.17	
	908764	16-Jul-26	136,682.58	
	912592	11-Sep-26	60,478.71	
	Total Invoices		227,594.01	
iii	Accrual to close		70,000.00	Estimate
	Total			297,594.01

2c Applicants' Counsel To Sept 8

i	Invoice #	Invoice Date	Invoice Amount	
	6673991	30-Apr-26	222,388.35	
	6700651	16-Jul-26	114,206.04	
	6708264	31-Jul-26	5,259.32	
	Total Invoices		341,853.71	
ii	Accrual to close		10,000.00	Estimate
	Total			351,853.71

2d Sinclair Range 21,235.30

2e Grand Arc 1,899.53

Total Professional Fees 935,420.62

3 KERP: Max: \$30,000 30,000.00

Estimated Remaining funds available before Undetermined Claims 135,275.84

4 Undetermined claims

Mr. Boersma

Per Boersma Affidavit No.3 200,817.25 Excluding sales taxes

Legal Costs 58,234.48 Legal costs to July 14, 2026, which were provided to the Monitor by email on the same date.

Total 259,051.73

Success Fee (5%) 197,450.24 Estimate calculated by the Monitor

Scenario: The claims under the Administration Charge do not exceed \$1,050,000

Estimated amount to Distribute to secured creditors in terms of priority 135,275.84

Scenario: The claims under the Administration Charge exceed \$1,050,000

Estimated amount to Distribute to secured creditors in terms of priority 20,696.46